Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Has Big Ambitions In Vaccines, With An Eye On Blockbuster Opportunities

Executive Summary

The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.

You may also be interested in...



Pharma Is Poised For A COVID-19 Recovery; Will Q2 Deliver?

The second quarter could mark a financial turning point for big pharma as demand rebounds from the pandemic, but variability remains across portfolios and therapeutic areas.

GSK Shingrix Shingles Vaccine Could Get CDC Panel Nod For Use In Immunocompromised Adults

Phase III trials found vaccine effectiveness was 68.2% in recipients with autologous hematopoietic stem cell transplant and 87.2% in those with hematologic malignancies, GSK tells Advisory Committee on Immunization Practices.

Sanofi Creates ‘Center Of Excellence’ In Pursuit Of mRNA Vaccine Rivals

Sanofi is beefing up its investment in mRNA vaccine technology with a 400m annual injection into a dedicated mRNA Center of Excellence as it seeks to be at the forefront of the next generation of candidates.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144596

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel